Application of iPS cell technology to cancer epigenome study: Uncovering the mechanism of cell status conversion for drug resistance in tumor

Pathology International

Volumn 64, Issue 7, 2014, Pages 299-308

  Matsuda, Yutaka ^a,b   Semi, Katsunori ^a,c   Yamada, Yasuhiro ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer cell reprogramming; Cell status transition; Drug resistant cancer cells; Epigenetic flexibility; Epigenetics; iPS cell technology

Indexed keywords

CANCER CELL; CANCER EPIGENETIC; CANCER RESEARCH; DNA MODIFICATION; EPIGENETICS; GENETIC REGULATION; HUMAN; NEOPLASM; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SOMATIC CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DRUG RESISTANCE; GENETIC EPIGENESIS; GENETICS; NEOPLASMS; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS;

EID: 84904686351     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12180     Document Type: Review

References (72)

1. Clarke MF, Dick JE, Dirks PB etal. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. 2006.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
4. Singh SK, Clarke ID, Terasaki M etal. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
5. Singh SK, Hawkins C, Clarke ID etal. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-10951.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E etal. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
8. Schepers AG, Snippert HJ, Stange DE etal. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-735.
9. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
10. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
11. Quintana E, Shackleton M, Foster HR etal. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell. 2010; 18: 510-523.
12. Roesch A, Fukunaga-Kalabis M, Schmidt EC etal. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-594.
13. Trumpp A, Wiestler OD. Mechanisms of disease: Cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 2008; 5: 337-347.
14. Sharma SV, Lee DY, Li B etal. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
15. Chicas A, Kapoor A, Wang X etal. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A 2012; 109: 8971-8976.
16. Bernstein BE, Mikkelsen TS, Xie X etal. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-326.
17. Chaffer CL, Marjanovic ND, Lee T etal. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
18. Shih IM, Wang TL, Traverso G etal. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci U S A 2001; 98: 2640-2645.
19. Preston SL, Wong WM, Chan AO etal. Bottom-up histogenesis of colorectal adenomas: Origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003; 63: 3819-3825.
20. Schwitalla S, Fingerle AA, Cammareri P etal. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013; 152: 25-38.
21. Kobayashi S, Yamada-Okabe H, Suzuki M etal. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012; 30: 2631-2644.
22. Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 2009; 11: R32.
23. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
24. Takahashi K, Tanabe K, Ohnuki M etal. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
25. Hotta A, Ellis J. Retroviral vector silencing during iPS cell induction: An epigenetic beacon that signals distinct pluripotent states. Journal of cellular biochemistry. 2008; 105: 940-948.
26. Woltjen K, Michael IP, Mohseni P etal. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458: 766-770.
27. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-775.
28. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85: 348-362.
29. Yu J, Hu K, Smuga-Otto K etal. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
30. Okita K, Matsumura Y, Sato Y etal. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8: 409-412.
31. Soufi A, Donahue G, Zaret KS. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 2012; 151: 994-1004.
32. Chen J, Liu H, Liu J etal. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet 2012; 45: 34-42.
33. Onder TT, Kara N, Cherry A etal. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012; 483: 598-602.
34. Samavarchi-Tehrani P, Golipour A, David L etal. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7: 64-77.
35. Li R, Liang J, Ni S etal. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7: 51-63.
36. Doege CA, Inoue K, Yamashita T etal. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012; 488: 652-655.
37. Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell reprogramming. Nat Rev Genet 2013; 14: 427-439.
38. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810-813.
39. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R. Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature 1998; 394: 369-374.
40. Gurdon JB. The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 1962; 10: 622-640.
41. Gurdon JB, Uehlinger V. 'Fertile' intestine nuclei. Nature 1966; 210: 1240-1241.
42. Laskey RA, Gurdon JB. Genetic content of adult somatic cells tested by nuclear transplantation from cultured cells. Nature 1970; 228: 1332-1334.
43. McKinnell RG, Deggins BA, Labat DD. Transplantation of pluripotential nuclei from triploid frog tumors. Science 1969; 165: 394-396.
44. Hochedlinger K, Blelloch R, Brennan C etal. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004; 18: 1875-1885.
45. Carette JE, Pruszak J, Varadarajan M etal. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-4042.
46. Kumano K, Arai S, Hosoi M etal. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012; 119: 6234-6242.
47. Miyoshi N, Ishii H, Nagai K etal. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 2010; 107: 40-45.
48. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122: 3502-3510.
49. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-734.
50. Xie S, Wang Z, Okano M etal. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 1999; 236: 87-95.
51. Robertson KD, Uzvolgyi E, Liang G etal. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291-2298.
52. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer 2001; 91: 205-212.
53. Tahiliani M, Koh KP, Shen Y etal. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
54. Auclair G, Weber M. Mechanisms of DNA methylation and demethylation in mammals. Biochimie 2012; 94: 2202-2211.
55. Cortellino S, Xu J, Sannai M etal. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011; 146: 67-79.
56. Inoue A, Shen L, Dai Q, He C, Zhang Y. Generation and replication-dependent dilution of 5fC and 5caC during mouse preimplantation development. Cell Res 2011; 21: 1670-1676.
57. Inoue A, Zhang Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 2011; 334: 194.
58. Yang H, Liu Y, Bai F etal. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32: 663-669.
59. Noushmehr H, Weisenberger DJ, Diefes K etal. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510-522.
60. Turcan S, Rohle D, Goenka A etal. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
61. Mardis ER, Ding L, Dooling DJ etal. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
62. Sasaki M, Knobbe CB, Munger JC etal. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659.
63. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: The nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206: 13-37.
64. Costa Y, Ding J, Theunissen TW etal. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013; 495: 370-374.
65. Kishigami S, Mizutani E, Ohta H etal. Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer. Biochem Biophys Res Commun 2006; 340: 183-189.
66. Rybouchkin A, Kato Y, Tsunoda Y. Role of histone acetylation in reprogramming of somatic nuclei following nuclear transfer. Biol Reprod 2006; 74: 1083-1089.
67. Blelloch R, Wang Z, Meissner A, Pollard S, Smith A, Jaenisch R. Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. Stem Cells 2006; 24: 2007-2013.
68. Huangfu D, Maehr R, Guo W etal. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795-797.
69. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer 2004; 4: 677-687.
70. Cremer T, Cremer C. Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat Rev Genet 2001; 2: 292-301.
71. Hubner MR, Eckersley-Maslin MA, Spector DL. Chromatin organization and transcriptional regulation. Curr Opin Genet Dev 2012; 23: 89-95.
72. Hikichi T, Matoba R, Ikeda T etal. Transcription factors interfering with dedifferentiation induce cell type-specific transcriptional profiles. Proc Natl Acad Sci U S A 2013; 110: 6412-6417.